Reuters logo
BRIEF-Revance announces positive 24-week duration of effect in interim results from phase 2 cervical dystonia trial
December 12, 2016 / 9:20 PM / a year ago

BRIEF-Revance announces positive 24-week duration of effect in interim results from phase 2 cervical dystonia trial

Dec 12 (Reuters) - Revance Therapeutics Inc :

* Revance Therapeutics Inc - RT002 injectable appeared to be generally safe and well-tolerated

* Revance Therapeutics Inc - RT002 injectable displayed clinically significant impact on cervical dystonia signs and symptoms

* Revance Therapeutics Inc - these RT002 results are preliminary, with final results expected in first half of 2017

* Revance announces positive 24-week duration of effect in interim results from phase 2 cervical dystonia trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below